Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Circulating Tumor DNA (ctDNA) Methylation Quantification As Diagnostic Biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs)

Fatemeh Khatami
ORCID logo ,
Leonardo Oliveira Reis
,
Mehdi Ebrahimi
,
Shirzad Nasiri
,
Seyed Mohammad Tavangar
,
Mahin Ahmadi Pishkuhi
,
Gita Shafiei
,
Ramin Heshmat
,
Seyed Mohammad Kazem Aghamir
* ORCID logo
Version 1 : Received: 15 April 2023 / Approved: 17 April 2023 / Online: 17 April 2023 (04:54:45 CEST)

How to cite: Khatami, F.; Oliveira Reis, L.; Ebrahimi, M.; Nasiri, S.; Tavangar, S.M.; Ahmadi Pishkuhi, M.; Shafiei, G.; Heshmat, R.; Aghamir, S.M.K. Circulating Tumor DNA (ctDNA) Methylation Quantification As Diagnostic Biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs). Preprints 2023, 2023040404. https://doi.org/10.20944/preprints202304.0404.v1 Khatami, F.; Oliveira Reis, L.; Ebrahimi, M.; Nasiri, S.; Tavangar, S.M.; Ahmadi Pishkuhi, M.; Shafiei, G.; Heshmat, R.; Aghamir, S.M.K. Circulating Tumor DNA (ctDNA) Methylation Quantification As Diagnostic Biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs). Preprints 2023, 2023040404. https://doi.org/10.20944/preprints202304.0404.v1

Abstract

Introduction: Circulating tumor DNA (ctDNA) is newly diagnosed tumor DNA that can easily represent a tumor’s genetic and epigenetic change. Pheochromocytomas (PCCs) and Paragangliomas (PGLs) are rare tumors of adrenal gland tissue that have the potential to be detected by ctDNA. We aimed to study the potential of the methylation status of RDBP, SDHB, and SDHC genes in ctDNA of PCCs/PGLs patients as a diagnostic biomarker. Materials and Methods: Clinical data, fresh frozen tissue, the blood of 12 PCCs/PGL patients, and the blood of 12 age/sex-matched normal patients were collected. The methylation status of RDBP, SDHB, and SDHC was compared between cases and controls by MS-HRM analysis. Results: Amongst six promoter regions of RDBP, SDHB, and SDHC, promoter methylation quantification of SDHCa and RDBPb was significantly different between PCCs/PGLs and controls. SDHCa was methylated in 49.93% of PCCs/PGLs cases vs. 8.33 % of control samples, p-value: 0.026, area under curve AUC=0.757, and RDBPb in 74.9% of PCCs/PGLs cases vs. 25.0% of control samples, p-value: 0.032, AUC=0.750. Conclusions: This study suggests the ctDNA potential for a less invasive source of tumor epigenetic modification in PCCs/PGLs malignancies. The SDHCa and RDBPb hypermethylation warrant further exploration as diagnostic tools for PCCs/PGLs.

Keywords

ctDNA; liquid biopsy; Methylation; SDHCa; RDBPb; Pheochromocytoma; Paraganglioma

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.